Magnetic versus standard technique for sentinel node biopsy in breast cancer

MAGnetic versus STAndard technique for sentinel node biopsy in breast cancer: a Randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN20200149

Enrollment

924

Registered

2014-12-15

Start date

2015-01-01

Completion date

Unknown

Last updated

2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Malignant neoplasm of breast

Interventions

SLNB with the standard combined technique (blue dye and radioisotope) or the new technique (magnetic tracer and hand-held magnetometer). Interventions are the injection of the radioisotope, blue dye a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with breast cancer scheduled for SLNB and who are clinically and radiologically node negative

Exclusion criteria

Exclusion criteria: 1. Known intolerance/hypersensitivity to iron or dextran compounds 2. Patients who decline to receive radioisotope for SLNB 3. Patients with a pacemaker or other implantable devices in the chest wall

Design outcomes

Primary

Measure	Time frame
1. Overall SLNB identification rate (proportion of successful SLNBs) with either the standard or the new technique 2. SLNB identification rate within the cohort of patients with involved nodes	—

Secondary

Measure	Time frame
1. Morbidity from SLNB (including staining and lymphoedema rate) 2. Locoregional recurrence 3. Cost effectiveness (health economics) 4. Patient-reported outcome measures (PROMS) with both techniques	—

Countries

Netherlands, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026